The Filing Desk

Arrowhead Pharmaceuticals vs Tarsus Pharmaceuticals

Arrowhead Pharmaceuticals ARWR · Tarsus Pharmaceuticals TARS · Biotechnology

Tarsus Pharmaceuticals reported revenue of $451 million in fiscal 2025, about the same as Arrowhead Pharmaceuticals' $451 million in fiscal 2026. Arrowhead Pharmaceuticals' revenue fell 45.6% in its latest year, and Tarsus Pharmaceuticals' grew 146.7%. Arrowhead Pharmaceuticals had an operating margin of -156.9%, against -15.7% at Tarsus Pharmaceuticals. Free cash flow was −$284 million at Arrowhead Pharmaceuticals and −$22 million at Tarsus Pharmaceuticals. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.

Side by side

Arrowhead PharmaceuticalsTarsus Pharmaceuticals
Latest fiscal yearFY2026, Sep 30, 2026FY2025, Dec 31, 2025
Revenue$451M$451M
Revenue growth−45.6%146.7%
Revenue growth a year, last 5 years26.7%—
Gross margin——
Operating margin−156.9%−15.7%
Net margin−160.6%−14.7%
Free cash flow−$284M−$22M
Free cash flow margin−63.0%−4.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count5.9%11.1%
Last close$47.78$80.28
P/E at the last close——
Insider trades, last 12 monthssold $37.3 millionsold $20.0 million
Piotroski F-score2 of 84 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arrowhead PharmaceuticalsTarsus Pharmaceuticals
Operating margin
Percent of revenue
Arrowhead PharmaceuticalsTarsus Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arrowhead PharmaceuticalsTarsus Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arrowhead Pharmaceuticals and Tarsus Pharmaceuticals pages.